


PHARMACOLOGY

An Introduction

Seventh Edition

HENRY HITNER
BARBARA NAGLE

**Mc
Graw
Hill**
Education





Pharmacology

An Introduction

7th
edition

Henry Hitner, Ph.D.

Professor Emeritus
Department of Neuroscience, Physiology, and
Pharmacology
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania

Adjunct Professor, Pharmacology
Physician Assistant Program
Drexel University
Philadelphia, Pennsylvania

Barbara Nagle, Ph.D.

President
Clinical Research Development and Education
III Associates
Bryn Mawr, Pennsylvania

Mc
Graw
Hill
Education



PHARMACOLOGY: AN INTRODUCTION, SEVENTH EDITION

Published by McGraw-Hill Education, 2 Penn Plaza, New York, NY 10121. Copyright © 2016 by McGraw-Hill Education. All rights reserved.
Printed in the United States of America. Previous editions © 2012, 2005, and 1999. No part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written consent of McGraw-Hill Education, including, but not limited to, in any network or other electronic storage or transmission, or broadcast for distance learning.

Some ancillaries, including electronic and print components, may not be available to customers outside the United States.

This book is printed on acid-free paper.

1 2 3 4 5 6 7 8 9 0 QVS/QVS 1 0 9 8 7 6 5

ISBN 978-0-07-351381-2

MHID 0-07-351381-4

Senior Vice President, Products & Markets: *Kurt L. Strand*
Vice President, General Manager, Products & Markets: *Marty Lange*
Vice President, Content Design & Delivery: *Kimberly Meriwether David*
Director: *Chad Grall*
Brand Manager: *William Mulford*
Product Developer: *Jessica Dimitrijevic*
Marketing Manager: *Harper Christopher*
Director of Development: *Rose Koos*
Digital Product Developer: *Katherine Ward*
Director, Content Design & Delivery: *Terri Schiesl*
Full-Service Manager: *Faye Schilling*
Content Project Managers: *Melissa M. Leick, Christina Nelson, Judi David*
Buyer: *Debra Sylvester*
Design: *Studio Montage, St. Louis, MO*
Content Licensing Specialists: *John Leland, Lorraine Buczek*
Cover Image: © *ImageDJ / Alamy / RF*
Compositor: *Laserwords Private Limited*
Typeface: *10/13 Times LT Std - Roman*
Printer: *Quad/Graphics*

All credits appearing on page or at the end of the book are considered to be an extension of the copyright page.

Library of Congress Cataloging-in-Publication Data

Hitner, Henry.

Pharmacology: an introduction.—7th edition / Henry Hitner, Ph.D., professor emeritus, Department of Neuroscience, Physiology, Pharmacology, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, adjunct professor, Pharmacology Physician Assistant Program, Drexel University, Philadelphia, Pennsylvania, Barbara Nagle, Ph.D. president, Clinical Research Development and Education III Associates, Bryn Mawr, Pennsylvania.

pages cm

Includes index.

ISBN 978-0-07-351381-2 (alk. paper)

1. Pharmacology. I. Nagle, Barbara T. II. Title.

RM300.H57 2016

615.1—dc23

2014044612

The Internet addresses listed in the text were accurate at the time of publication. The inclusion of a website does not indicate an endorsement by the authors or McGraw-Hill Education, and McGraw-Hill Education does not guarantee the accuracy of the information presented at these sites.

Brief Contents

About the Authors xviii

Preface xix

What Every Student Needs to Know xxiv

1. Pharmacology: An Introduction 4
2. Pharmacokinetics and Factors of Individual Variation 17
3. Geriatric Pharmacology 34
4. Math Review and Dosage Calculations 43
5. Introduction to the Autonomic Nervous System 58
6. Drugs Affecting the Sympathetic Nervous System 68
7. Drugs Affecting the Parasympathetic Nervous System 85
8. Drugs Affecting the Autonomic Ganglia 99
9. Skeletal Muscle Relaxants 106
10. Local Anesthetics 123
11. Introduction to the Central Nervous System 138
12. Sedative-Hypnotic Drugs and Alcohol 146
13. Antipsychotic and Antianxiety Drugs 161
14. Antidepressants, Psychomotor Stimulants, and Lithium 175
15. Psychotomimetic Drugs of Abuse 188
16. Antiepileptic Drugs 200
17. Antiparkinson Drugs 212
18. General Anesthetics 225
19. Opioid Analgesics 248
20. Nonopioid Analgesics, Nonsteroidal Anti-inflammatories,
and Anticancer Drugs 272
21. Review of Cardiac Physiology and Pathology 304



22.	Treatment of Heart failure	312
23.	Antiarrhythmic Drugs	326
24.	Antianginal Drugs	341
25.	Diuretics	352
26.	Antihypertensive Drugs	373
27.	Anticoagulants and Coagulants	388
28.	Nutrition and Therapy	409
29.	Hypolipidemic Drugs	431
30.	Antianemics	451
31.	Antihistaminic Drugs and Mast Cell Stabilizers	468
32.	Respiratory Pharmacology, Treatment of Asthma, and COPD	485
33.	Therapy of Gastrointestinal Disorders: Peptic Ulcers, GERD, and Vomiting	502
34.	Agents That Affect Intestinal Motility	529
35.	Introduction to the Endocrine System	546
36.	Adrenal Steroids	557
37.	Gonadal Hormones, Oral Contraceptives, and Erectile Dysfunction Drugs	575
38.	Drugs Affecting the Thyroid and Parathyroid Glands and Bone Degeneration	601
39.	Pancreatic Hormones and Antidiabetic Drugs	620
40.	Posterior Pituitary Hormones: Antidiuretic Hormone and Oxytocin	653
41.	Antibacterial Agents	666
42.	Antifungal and Antiviral Drugs	687
43.	Parasitic Infections: Antiprotozoal and Anthelmintic Drugs	721
44.	Antiseptics and Disinfectants	737
45.	Antineoplastic Agents	754
46.	Immunopharmacology	771
	Glossary	783
	Appendix A Latin Abbreviations Used in Medicine	798
	Appendix B Abbreviations and Symbols Commonly Used in Medical Notations	799
	Photo Credits	803
	Index	805

Table of Contents

PART 1

General Concepts 3

CHAPTER 1

Pharmacology: An Introduction 4

- Drug Sources and Major Areas of Pharmacology 5
- Terminology Related to Drug Effects 6
- Basic Concepts in Pharmacology 7
- Dose-Response and Time-Plasma Drug Concentration Curves 8
- Drug Safety 9
- Drug Nomenclature 10
- Drug References and Drug Legislation 10
- Chapter Review 13

CHAPTER 2

Pharmacokinetics and Factors of Individual Variation 17

- Drug Forms and Routes of Administration 18
- Pharmacokinetic Processes 20
- Clinical Factors that Determine the Intensity of Drug Response 23
- Factors of Individual Variation 25
- Pharmacokinetic Considerations for Pediatrics 26
- Drug Interactions 28
- Terminology Associated with Chronic Drug Use and Abuse 28
- Chapter Review 30

CHAPTER 3


Geriatric Pharmacology 34

- Drug Use in the Elderly 35
- Drug Absorption and Distribution 35
- Drug Metabolism and Excretion 36
- Effects of Age on Drug Response 37
- Drug Compliance in the Elderly 38
- Chapter Review 40

CHAPTER 4

Math Review and Dosage Calculations 43

- Fractions, Decimals, and Percents 44
- Dosage Calculations 46



Systems of Measurement 46
Calculating Dosages 48
Pediatric Dosage Calculations 49
Monitoring IV Infusion Rates 50
Chapter Review 52

PART 2

Pharmacology of the Peripheral Nervous System 57

CHAPTER 5


Introduction to the Autonomic Nervous System 58
Nervous System Organization 59
Overview of the ANS 60
Parasympathetic and Sympathetic Divisions 60
ANS Nerve Fibers and Neurotransmitters 63
Cholinergic and Adrenergic Receptors 65
Chapter Review 66

CHAPTER 6

Drugs Affecting the Sympathetic Nervous System 68
Adrenergic Nerve Endings 69
Adrenergic Receptors 70
Adrenergic Drug Classes 71
Alpha-Adrenergic Drugs 72
Beta-Adrenergic Drugs 73
Alpha-Adrenergic Blocking Drugs 75
Beta-Adrenergic Blocking Drugs 76
Adrenergic Neuronal Blocking Drugs 78
Chapter Review 82

CHAPTER 7

Drugs Affecting the Parasympathetic Nervous System 85
Cholinergic Nerve Activity 86
Cholinergic Receptors 86
Cholinergic Drugs 88
Clinical Indications for Anticholinesterase Drugs 91
Anticholinergic Drugs 93
Preferred Treatment for Selected Conditions 94
Chapter Review 96



CHAPTER 8

Drugs Affecting the Autonomic Ganglia 99

- Ganglionic Stimulants 100
- Drugs Used in Smoking Cessation 100
- Ganglionic Blockers 102
- Drug Interactions with Ganglionic Blocking Drugs 103
- Chapter Review 104

CHAPTER 9

Skeletal Muscle Relaxants 106

- Skeletal Muscle Relaxation 108
- Peripherally Acting Skeletal Muscle Relaxants 108
- Major Adverse Effects Associated with Peripheral NMB 112
- Direct-Acting Skeletal Muscle Relaxants 114
- Centrally Acting Skeletal Muscle Relaxants (Spasmolytics) 115
- Preferred Treatment for Selected Conditions 117
- Chapter Review 120

CHAPTER 10

Local Anesthetics 123

- How Local Anesthetics Work 124
- Types of Local Anesthetics 125
- Types of Local Anesthesia 126
- Adverse Effects Associated with Local Anesthetics Use 130
- Clinical Applications 130
- Special Considerations 131
- Chapter Review 133


PART 3

Pharmacology of the Central Nervous System 137

CHAPTER 11

Introduction to the Central Nervous System 138

- Structural and Functional Features of the Brain 139
- Diencephalon and Brainstem 140
- Cerebellum 141
- Spinal Cord 141
- Functional Components 141
- Chapter Review 143



CHAPTER 12

Sedative-Hypnotic Drugs and Alcohol 146

- Sleep Cycle 148
- Mechanism of Action of Sedative-Hypnotic Drugs 149
- Barbiturate Sedatives and Hypnotics 149
- Benzodiazepines 152
- Miscellaneous Hypnotic Drugs 154
- Alcohol 155
- Chapter Review 158

CHAPTER 13

Antipsychotic and Antianxiety Drugs 161

- Antipsychotic Drugs 162
- Phenothiazines 163
- Butyrophenones 164
- Thioxanthenes 165
- Atypical Antipsychotic Drugs 166
- Antianxiety Drugs 167
- Chapter Review 172

CHAPTER 14

Antidepressants, Psychomotor Stimulants, and Lithium 175

- Types of Depression 176
- Selective Serotonin Reuptake Inhibitors (SSRIs) 177
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 178
- Tricyclic Antidepressants 179
- Monoamine Oxidase Inhibitors (MAOIs) 180
- Antidepressants with Additional Mechanisms of Action 182
- Psychomotor Stimulants 182
- Lithium 183
- Preferred Therapy for Depression, Mania, and Bipolar Disorder 184
- Chapter Review 185

CHAPTER 15

Psychotomimetic Drugs of Abuse 188

- LSD-Type Hallucinogens 189
- Psychomotor Stimulants 191
- Phencyclidine 194
- Marijuana 194
- Chapter Review 197

CHAPTER 16

Antiepileptic Drugs 200

- Types of Epilepsy 201
- Drugs Effective for Both Generalized Tonic-Clonic and Partial Seizures 202
- Drugs Effective Primarily For Partial Seizures 206
- Drugs Used in the Treatment of Absence Seizures 206
- Treatment of Status Epilepticus 207
- Preferred Therapy for Epileptic Seizures 207
- Chapter Review 209

CHAPTER 17

Antiparkinson Drugs 212

- Neurotransmitters Affecting the Basal Ganglia 213
- Drugs that Form Dopamine 215
- Drugs that Inhibit Metabolism of Levodopa and DA 216
- Dopamine Receptor Agonists 219
- Miscellaneous Drugs 219
- Preferred Therapy for Parkinson's Disease 220
- Chapter Review 222

CHAPTER 18

General Anesthetics 225

- Types of Anesthesia 227
- Characteristics of General Anesthesia 228
- Mechanism of Action of General Anesthetics 229
- Classes of General Anesthetics 231
- Nonanesthetic Effects of General Anesthetics 236
- Adjunct Medications Used in General Anesthesia 239
- Special Considerations with General Anesthetic Use 242
- Preferred Use of Anesthetics 244
- Chapter Review 245

CHAPTER 19

Opioid Analgesics 248

- Pathways for Pain Recognition 250
- Clinical Indications 251
- Opioid Analgesics 251
- Sites and Mechanism of Opioid Action 253
- Nonanalgesic Opioid Effects 256
- Drug Administration and Disposition 258

Adverse Effects, Cautions, and Contraindications 259
Treatment of Physical Dependence and Respiratory Depression 260
Opioid Antitussives 263
Chapter Review 268

CHAPTER 20

Nonopioid Analgesics, Nonsteroidal Antiinflammatories, and Antigout Drugs 272

Mediators of Inflammation 273
Drugs that Suppress Inflammation 276
Clinical Indications 279
Actions of Nonopioid Anti-inflammatory Analgesics 279
Adverse Effects, Toxicities, and Contraindications 287
Drugs Useful in Treating Gout 290
Chapter Review 297

PART 4

Pharmacology of the Heart 303

CHAPTER 21

Review of Cardiac Physiology and Pathology 304

Cardiac Muscle 305
Conduction System 305
The Electrocardiogram 307
Cardiac Nerve Supply 307
Main Diseases of the Heart 308
Chapter Review 309

CHAPTER 22

Treatment of Heart Failure 312

Chronic Heart Failure (CHF) 313
Diuretic Therapy of CHF 314
Vasodilator Therapy of CHF 316
Use of Adrenergic Beta-Blockers in CHF 317
Cardiac Glycosides 318
Chapter Review 323

CHAPTER 23

Antiarrhythmic Drugs 326

Types of Arrhythmias 327
Electrophysiology of the Heart 329



Class 1 Antiarrhythmic Drugs: Sodium Channel Blockers	331
Class 2 Antiarrhythmic Drugs: Beta-Blockers	333
Class 3 Antiarrhythmic Drugs: Potassium Channel Blockers	334
Class 4 Antiarrhythmic Drugs: Calcium Channel Blockers	334
Special Considerations and Preferred Therapy for Selected Arrhythmias	336
Chapter Review	338

CHAPTER 24

Antianginal Drugs 341

Classification of Angina Pectoris	342
Nitrates	343
Beta-Adrenergic Blocking Drugs	345
Calcium Channel Blockers	346
Preferred Therapy for Treatment of Angina Pectoris	347
Chapter Review	348

PART 5

Pharmacology of the Vascular and Renal Systems 351

CHAPTER 25

Diuretics 352

Clinical Indications for Diuretic Use	354
Renal Physiology and Conditions Associated with Renal Dysfunction	354
Osmotic Diuretics	359
Carbonic Anhydrase Inhibitors	359
Thiazide and Thiazide-Like Diuretics	362
Organic Acid (Loop) Diuretics	363
Potassium-Sparing Diuretics	364
ADH Antagonists and Miscellaneous Diuretics	365
Preferred Treatment, Adverse Effects, and Drug Interactions	366
Chapter Review	370

CHAPTER 26

Antihypertensive Drugs 373

Physiological Factors that Determine Blood Pressure	374
Factors Affecting Blood Pressure	376
Diuretics	376
Drugs that Reduce Sympathetic Activity	379
Vasodilator Drugs	380



Drugs that Reduce the Activity of Angiotensin II	380
Treatment of Hypertensive Crisis	383
Patient Education and Monitoring	383
Preferred Therapy for Treatment of Hypertension	383
Chapter Review	385

CHAPTER 27

Anticoagulants and Coagulants 388

Blood Clot Formation	389
Anticoagulant Mechanisms of Action	391
Characteristics of the Heparins	393
Oral Anticoagulants	395
Antiplatelet Drugs	398
Special Considerations, Contraindications and Drug Interactions with Anticoagulants	399
Fibrinolytic/Thrombolytic Drugs	402
Clinical Uses of Coagulants/Hemostatics	404
Chapter Review	406

CHAPTER 28

Nutrition and Therapy 409

Nutrients and U.S. Daily Allowance Recommendations	410
Dietary Recommendations	411
Function of Vitamins	414
Fat-Soluble Vitamins A, D, E, K	415
Water-Soluble Vitamins B and C	419
Body Water and Fluid Balance	421
Minerals	422
Intravenous Therapy	425
Chapter Review	427

CHAPTER 29

Hypolipidemic Drugs 431

Atherosclerosis and Arterial Disease	433
Lipids, Lipoproteins, and Cholesterol	433
Classes of Hypolipidemic Drugs	437
HMG-CoA Reductase Inhibitors: Statins	437
Cholesterol Absorption Inhibitors: Ezetimibe	441
Bile Acid Sequestrants: Cholestyramine, Colestipol, and Colesevelam	443
Other Hypolipidemic Drugs	443
Contraindications and Drug Interactions	445
Chapter Review	448

CHAPTER 30

Antianemics 451

Anemia and Red Blood Cell (RBC) Function 452

Iron Deficiency Anemia 453

Treatment of Iron Deficiency: Hematinics 455

Cobalamin Deficiency Anemia 457

Folic Acid Deficiency 459

Erythropoietin Deficiency Anemia 461

Chapter Review 463

PART 6

Drugs That Affect the Respiratory System 467

CHAPTER 31

Antihistaminic Drugs and Mast Cell Stabilizers 468

Allergy: The Role of Histamine 469

Effects of Histamine 470

Antihistamine H₁ Antagonists 472

Mast Cell Stabilizers 478

Chapter Review 482

CHAPTER 32

Respiratory Pharmacology, Treatment of Asthma, and COPD 485

Respiratory Diseases 486

Chemical Mediators 488

Role of the Autonomic Nervous System 489

Bronchodilator Drugs 490


Anti-inflammatory Drugs 493

Antiallergic Agents 495

Mucolytics and Expectorants 495

Preferred Therapy for Asthma and COPD 496

Chapter Review 497



PART 7


Pharmacology of the GI Tract 501

CHAPTER 33

Therapy of Gastrointestinal Disorders: Peptic Ulcers, GERD, and Vomiting 502

Process of Digestion 503

Peptic Ulcer and GERD 505



Management of Gastrointestinal Disorders	507
Antisecretory Drugs: Suppression of Gastric Acid	510
Acid Neutralization: Antacids	515
Barrier Enhancers: Sucralfate	517
Prokinetic Drugs for the Management of GERD	518
Management of Emesis	519
Drugs that Inhibit Vomiting: Antiemetics	520
Chapter Review	526

CHAPTER 34

Agents That Affect Intestinal Motility 529

Bowel Function	531
Diarrhea	531
Treatment of Simple Diarrhea	533
Causes of Constipation	535
Types of Laxatives Used in the Management of Constipation	536
Chapter Review	541

PART 8

Pharmacology of the Endocrine System 545

CHAPTER 35

Introduction to the Endocrine System 546

Basic Hormone Function	547
Hypothalamic-Pituitary Axis	549
Regulating Hormone Secretion	550
Endocrine Functions of The Anterior Pituitary Gland	551
Chapter Review	554

CHAPTER 36

Adrenal Steroids 557

Regulation of Adrenocorticoid Hormones	558
Primary Function of the Glucocorticoids	560
Clinical Uses of Glucocorticoids	561
Function of Mineralocorticoid Aldosterone	567
Special Cautions and Drug Interactions	569
Chapter Review	572

CHAPTER 37

Gonadal Hormones, Oral Contraceptives, and Erectile Dysfunction Drugs 575

Female Sex Hormones	577
Clinical Uses of Estrogen and Progestins	578



Contraception: Oral Contraceptives and Hormone Delivery Systems	580
Hormonal Replacement Therapy (HRT)	585
Other Clinical Uses of Estrogens and Progestogens	587
Fertility Drugs	588
Male Sex Hormones	590
Erectile Dysfunction	595
Chapter Review	598

CHAPTER 38

Drugs Affecting the Thyroid and Parathyroid Glands and Bone Degeneration	601
Function and Regulation of the Thyroid Gland	602
Effects of Thyroid Hormone Hyposecretion	604
Thyroid Hormone Replacement Therapy for Hypothyroidism	605
Effects of Thyroid Hormone Hypersecretion	607
Drugs Used to Treat Hyperthyroidism	608
Parathyroid Hormones: Role of Parathormone	610
Degenerative Bone Disease: Osteoporosis	613
Drugs Used for Bone Disorders	614
Chapter Review	617

CHAPTER 39

Pancreatic Hormones and Antidiabetic Drugs	620
Pancreatic Endocrine Function	622
Diabetes Mellitus	625
Treatment of Diabetes	627
Antidiabetic Drugs: Insulins	628
Parenteral Antidiabetic Drugs: Amylin Analog and Incretin Mimetics	636
Oral Antidiabetic Drugs: Secretagogues, Hypoglycemics	638
Other Oral Antihyperglycemic Drugs	642
Chapter Review	649


CHAPTER 40

Posterior Pituitary Hormones: Antidiuretic Hormone and Oxytocin	653
Posterior Pituitary Hormones	654
Antidiuretic Hormone (ADH)	654
Diabetes Insipidus	656
Function and Clinical Use of Oxytocin	657
Tocolytics	658
Chapter Review	661

CHAPTER 41

Antibacterial Agents 666

- Morphology of Bacteria 667
- Chemotherapy 668
- Penicillins 670
- Cephalosporins 673
- Aminoglycosides 675
- Tetracyclines 676
- Sulfonamides 677
- Macrolide Antibiotics 678
- Fluoroquinolone Antimicrobials 679
- Miscellaneous Antimicrobial Drugs 680
- Drugs Used to Treat Tuberculosis 681
- Preferred Therapy for Selected Infections 682
- Chapter Review 684

**CHAPTER 42**

Antifungal and Antiviral Drugs 687

- Fungal Infections 689
- Antifungal Drugs 691
- Systemic Antifungal Drugs 694
- Oral and Topical Antifungal Drugs 697
- Viral Diseases 700
- Antiviral Drugs 706
- Mechanisms of Action 709
- Characteristics of Antiviral Drugs 713
- Chapter Review 718

CHAPTER 43

Parasitic Infections: Antiprotozoal and Anthelmintic Drugs 721

- Parasitic Infections: Protozoa and Worms 722
- Drugs Effective in the Treatment of Malaria (Antimalarial Drugs) 724
- Drugs Effective in the Treatment of Dysentery 726
- Other Protozoal Infections and Drug Treatment 728
- Drug Treatment of Parasitic Worm Infestations 730
- Chapter Review 734

CHAPTER 44

Antiseptics and Disinfectants 737

- The Role of Antiseptics and Disinfectants 738
- Categories of Antisepsis and Disinfection 739
- Clinical Uses of Antiseptics and Disinfectants 743
- Common Chemicals that Inhibit Infectious Microorganisms 743
- Adverse Effects and Special Cautions 747
- Chapter Review 748

PART 10

Antineoplastics and Drugs Affecting the Immune System 753

CHAPTER 45

Antineoplastic Agents 754

- Types of Cancer 755
- Alkylating Drugs 757
- Antimetabolites 760
- Drugs Derived from Natural Products 762
- Hormone Antagonists 763
- New Approaches to Cancer Chemotherapy 766
- Chapter Review 768

CHAPTER 46

Immunopharmacology 771

- Immune System 772
- Immunosuppressive Drugs 773
- Immunomodulating Drugs 778
- Chapter Review 780


Glossary 783

Appendix A: Latin Abbreviations Used in Medicine 798

Appendix B: Abbreviations and Symbols Commonly Used in Medical Notations 799

Photo Credits 803

Index 805





About the Authors

Henry Hitner earned a bachelor of science degree in biology from Moravian College in Bethlehem, Pennsylvania, and spent several years working in the pharmaceutical industry, first as a research assistant in toxicology for Wyeth Laboratories and then as a research pharmacologist for National Drug Company, both in Philadelphia. During this time he earned a master of education degree in biology from West Chester University. He attended graduate school at Hahnemann Medical College in Philadelphia, where he earned a PhD in pharmacology. Dr. Hitner then went into academia, where he held numerous faculty positions, first as an instructor of biology and allied health sciences at Montgomery County Community College, followed by 30 years of teaching and research at the Philadelphia College of Osteopathic Medicine (PCOM). At PCOM he served as professor and vice chair of the neuroscience, physiology, and pharmacology department. Other positions included director of the animal facility and chair of the institutional animal care and utilization committee. Professional memberships included the Sigma Xi Scientific Research Society and the American Society for Pharmacology and Experimental Therapeutics. He was the recipient of the Lindback Foundation Award for Distinguished Teaching and a Mentor Award from the National Student Association. Henry and his wife Carlotta enjoy traveling, the beach, and time spent with family and their nine grandchildren.

Barbara Nagle earned a master of science and doctorate at Hahnemann Medical College and University in the department of pharmacology. Following postdoctoral training in ocular pharmacology at Will's Eye Hospital, Philadelphia, she taught pharmacology and physiology to medical students at the Philadelphia College of Osteopathic Medicine (PCOM) and to nursing students at Widener University. After several years in academia, she moved into the pharmaceutical industry at Glaxo Smith-Kline, Endo Pharmaceuticals, Bio-Pharm Clinical Services, ICON, and InKine Pharmaceuticals, Inc. as Director of Clinical Information and later Vice President of Clinical Research, Training and Quality Assurance. She has been part of the research effort to bring products through clinical development to FDA approval such as gastric acid suppressants (antihistamines), beta-blockers, antiinfectives, muscle relaxants, and oral contraceptives. Her most recent affiliation was with Endo Pharmaceuticals in pain management research prior to her current activities as consultant and educator. She has served as International Director of Drug Development Training and Medical Education for BioPharm. Professional memberships include the Sigma Xi Scientific Research and American Medical Writers Association. Barbara is a freelance photographer, traveler, and silk painter.

The seventh edition of *Pharmacology: An Introduction* has been thoroughly updated, but the aim of this program remains what it has always been: to present a clear understanding of the basic concepts of pharmacology to the beginning student. Pharmacology is a complex subject that requires basic knowledge in many different scientific disciplines, particularly anatomy, physiology, and pathology. Health profession students often have limited exposure to these subjects, and one of the objectives of our text is to provide the necessary background information and to refresh the students' memory of previously learned material through which the therapeutic action of drugs can be clearly understood.

The goal of this text is to explain the **mechanisms of action of drugs**. Understanding how drugs produce their effects allows the student to better understand the different pharmacologic actions and adverse effects that drugs produce. *Pharmacology: An Introduction* is designed for a variety of health profession programs requiring an understanding of pharmacology. The book presents a basic rationale for understanding current drug therapy. The drug information and chapter features are designed to be applicable and adaptable to many different educational programs. Personnel in the health and nursing professions spend much of their working time in direct contact with patients—observing, treating, and administering to the countless requirements and demands that constitute effective and responsible patient care. Therefore, it is important that students in health professions acquire a sound basic understanding of pharmacology as it relates to their particular needs.

New scientific discoveries and advances in the understanding of disease provide a continual introduction and approval of new drugs. At the same time, older drug therapies and drugs that cause serious adverse effects or other problems are eliminated. New advances in genetics and molecular biology have allowed the development of monoclonal antibodies and drugs with more selective mechanisms of action. These new agents can target specific receptors and physiologic functions that more accurately focus on the pathology of a particular disease process. Thus pharmacology is an ever-changing, growing body of knowledge that continually demands greater amounts of time and education from those in the health professions.

Organization

Pharmacology: An Introduction is organized into **10 sections**. The introductory section, *General Concepts*, presents the basic concepts and pharmacologic

principles that apply to all drugs. Subsequent sections present the drug classes that pertain to a specific body organ system (nervous, cardiovascular, respiratory, etc.) or therapeutic indication (antihypertensives, infectious diseases, antineoplastics, etc.). The discussion of each drug classification concentrates on the mechanisms of action, main therapeutic effects, clinical indications, adverse reactions, and drug interactions.

Features

Pharmacology: An Introduction's hallmark features include:

- **Readability:** Short readable chapters that link theory to practice.
- **Need-to-know Information:** The content is focused on need-to-know information, so not to overload the learner.
- **Patient Administration and Monitoring Boxes:** These features provide the student with critical patient information and patient instructions regarding the drugs discussed in the chapter.

Other key features:

- **Learning Outcomes (LOs)** The learning outcomes have been completely revised in this edition. As always, the LOs are correlated to the Revised Bloom's Taxonomy and are numbered at the beginning of each chapter. Learning Outcomes are linked to the main chapter topic headings, the end-of-chapter review questions, exam questions, instructor resources, and all content in Connect. This allows the student to more quickly associate the LOs with the location of that information in the text and with the answers to the review questions.
- **Notes to the Health-Care Professional** emphasize important points and information for medical personnel involved in drug administration.
- **Chapter reviews** at the end of each chapter progress from simple to complex and provide immediate reinforcement of terminology and pharmacological concepts important for acquiring knowledge. The clinically relevant on-the-job questions allow students more opportunity to practice critical-thinking skills.

What's New?

- Revision and numbering of all learning outcomes to reflect the Revised Bloom's Taxonomy guide the student on a clear path to mastering chapter content.





- Correlation of learning outcomes to all major chapter headings and end-of-chapter review questions will help the student and instructor focus on key chapter content.
- Over 140 revised tables organize and summarize the main pharmacologic features of the different drug classes. **The tables list the generic drug name first followed by the trade name(s), which are italicized and put within parentheses.** These drug tables are particularly useful for students in health information management programs.

Updated drug information has been found by using several key sources:

- US Federal Drug Administration (FDA) provides daily updates on drug approvals, drug safety issues, medication guides, and drug industry information.
- FDA database on drug approvals and discontinuations is used to check status of market availability of branded and generic drugs.
- *www.centerwatch.com* by Jobson Medical Information, LLC, is a leading source of information about the clinical trials (pharmaceutical drugs and devices) industry.
- *www.factsandcomparisons.com* by Wolters Kluwer Health is a searchable database by drug name or therapeutic category for all FDA-approved drugs.
- National Library of Medicine and National Institutes of Health Medical provide information on conditions, diseases, wellness, over-the-counter (OTC) and prescription medication at different levels to facilitate understanding by professionals, students, patients, and consumers.
- WebMD Health Professional Network provides evidence-based content, updated regularly by more than 8000 attributed physician or health care provider authors and editors, and the latest practice guidelines in 38 clinical areas. It is reviewed by physicians at Harvard University Medical School.
- Aetna *InteliHealth* provides credible information from trusted sources, including Harvard Medical School and Columbia University College of Dental Medicine.
- Professional Organizations are dedicated to providing accurate information to patients and health-care providers on a specific disease or condition.

In addition to providing innovative approaches to learning pharmacology, McGraw-Hill Education knows how much effort it takes to prepare for a new course. Through focus groups, symposia, reviews, and conversations with

instructors like you, we have gathered information about the materials you need in order to facilitate successful courses. We are committed to providing you with high-quality, accurate instructor support.

Digital Resources

Knowing the importance of flexibility and digital learning, McGraw-Hill Education has created multiple assets to enhance the learning experience no matter what the class format: traditional, online, or hybrid. This product is designed with digital solutions to help instructors and students be successful.



connect[®]

Learn without Limits: McGraw-Hill Connect[®]

Continually evolving, McGraw-Hill Connect has been redesigned to provide the only true adaptive learning experience delivered within a simple and easy-to-navigate environment, placing students at the very center.

- Performance Analytics—Now available for both instructors and students, easy-to-decipher data illuminate course performance. Students always know how they're doing in class, while instructors can view student and section performance at a glance.
- Mobile—With material available on tablets, students can now access assignments, quizzes, and results on-the-go, and instructors can assess student and section performance anytime, anywhere.
- Personalized Learning—Squeezing the most out of study time, the adaptive engine in Connect creates a highly personalized learning path for each student by identifying areas of weakness, and surfacing learning resources to assist in the moment of need. This seamless integration of reading, practice, and assessment ensures that the focus is on the most important content for that individual student at that specific time, while promoting long-term retention of the material. Learn more at <http://connect.mheducation.com>.



LEARNSMART[®]

A D V A N T A G E

Learning at the Speed of You: LearnSmart Advantage Suite

LearnSmart Advantage is a series of adaptive learning products fueled by LearnSmart, the most widely used and intelligent adaptive resource proven to improve learning since 2009. Developed to deliver demonstrable

results in boosting grades, increasing course retention, and strengthening memory recall, LearnSmart Advantage spans the entire learning process from course preparation through final exams. LearnSmart Advantage also provides the first and only adaptive reading experience in SmartBook. Distinguishing what students know from what they don't, and honing in on concepts they are most likely to forget, each product in the series helps students study smarter and retain more knowledge. A smarter learning experience for students coupled with valuable reporting tools for instructors, and available in hundreds of course areas, LearnSmart Advantage is advancing learning like no other products in higher education today. **Go to** www.LearnSmartAdvantage.com for more information.



Record and Distribute Your Lectures for Multiple Viewing: My Lectures—Tegrity

McGraw-Hill Tegrity records and distributes your class lecture with just a click of a button. Students can view it anytime and anywhere via computer, iPod, or mobile device. It indexes as it records your PowerPoint presentations and anything shown on your computer, so students can use keywords to find exactly what they want to study. Tegrity is available as an integrated feature of **McGraw-Hill Connect** and as a stand-alone product.

The Best of Both Worlds



A Single Sign-on with Connect and Your Blackboard Course: McGraw-Hill Education and Blackboard—for a Premium User Experience

Blackboard, the Web-based course management system, has partnered with McGraw-Hill Education to allow students and faculty to use online materials and activities better, in order to complement face-to-face teaching. Blackboard features exciting social learning and teaching tools that foster active learning opportunities for students. You'll transform your closed-door classroom into communities where students remain connected to their educational experience 24 hours a day.

This partnership allows you and your students access to McGraw-Hill's Connect and Create right from within your Blackboard course—all with a single sign-on. You get not only single sign-on with Connect and Create, but also deep integration of McGraw-Hill Education content and content engines right in Blackboard. Whether you're choosing a book for your course or building Connect assignments, all the tools you need are right where you want them—inside Blackboard. Gradebooks are now seamless. When a student completes an integrated Connect assignment, the grade for that assignment automatically (and instantly) feeds into your Blackboard grade center. McGraw-Hill Education and Blackboard can now offer you easy access to industry's leading technology and content, whether your campus hosts it or we do. Be sure to ask your local McGraw-Hill Education representative for details.



Still Want Single Sign-on Solutions and Using Another Learning Management System?

See how **McGraw-Hill Campus** makes the grade by offering universal sign-on, automatic registration, gradebook synchronization and open access to a multitude of learning resources—all in one place. MH Campus supports Active Directory, Angel, Blackboard, Canvas, Desire2Learn, eCollege, IMS, LDAP, Moodle, Moodlerooms, Sakai, Shibboleth, WebCT, BrainHoney, Campus Cruiser, and Jenzibar eRacer. Additionally, MH Campus can be easily connected with other authentication authorities and LMSs. Visit <http://mhcampus.mhhe.com/> to learn more.



Create a Textbook Organized the Way You Teach: McGraw-Hill Education Create

With Create, you can easily rearrange chapters, combine material from other content sources, and quickly upload content you have written, such as your course syllabus or teaching notes. Find the content you need in Create by searching through thousands of leading McGraw-Hill Education textbooks. Arrange your book to fit your teaching style. Create even allows you to personalize





your book's appearance by selecting the cover and adding your name, school, and course information. Order a Create book and you'll receive a complimentary print review copy in 3 to 5 business days or a complimentary electronic review copy (eComp) via e-mail in minutes. Go to www.mcgrawhillcreate.com today and register to experience how Create empowers you to teach *your* students *your* way.

Best-in-Class Digital Support

Based on feedback from our users, McGraw-Hill Education has developed digital success programs that will provide you and your students the help you need, when you need it.

- **Training for Instructors:** Get ready to drive classroom results with our **Digital Success Team**—ready to provide in person, remote, or on-demand training as needed.
- **Peer Support and Training:** No one understands your needs like your peers. Get easy access to knowledgeable digital users by joining our Connect Community, or speak directly with one of our **Digital Faculty Consultants**, who are instructors using McGraw-Hill Education digital products.
- **Online Training Tools:** Get immediate anytime, anywhere access to modular tutorials on key features through our **Connect Success Academy**.

Get started today. Learn more about McGraw-Hill Education's Digital Success Programs by contacting your local sales representative or visit <http://connect.customer.mheducation.com/start>.

Need Help? Contact the McGraw-Hill Education Customer Experience Group (CXG)

Visit the CXG Web site at www.mhhe.com/support. Browse our FAQs (frequently asked questions) and product documentation and/or contact a CXG representative. CXG is available Sunday through Friday.

Additional Instructor Resources

- **Instructor's Manual** with course overview, lesson plans, answers for end-of-chapter exercises, competency correlations, Asset maps, and more.
- **PowerPoint Presentations** for each chapter, containing teaching notes correlated to learning outcomes. Each presentation seeks to reinforce key concepts and provide an additional visual aid for students.
- **Test Bank** and answer key for use in class assessment. The comprehensive test bank includes a variety of question types, with each question linked directly to a learning outcome from the text. Questions are also tagged with relevant topic, Bloom's Taxonomy level, difficulty level, and competencies. The test bank is available in Connect. Word and EZ Test versions are also available.

Acknowledgments

A sincere thanks to our reviewers and contributors who helped shape the development of the seventh edition.

Reviews

Eli Alvarado, RN, MHA, CPC

Nashville State Technical Community College

Norman Boisse

Northeastern University

Darlene Cantu

San Antonio College

Patricia Dominguez, RN, MSN

Houston Baptist University

Richard Espinosa, RPh, PharmD

Austin Community College

Ruby Johnson, MSN

Ozarka College

Vicky King, RN, MS, CNE

Cochise College

Robert Koch, PhD

University of Memphis

Matthew Robinson

University of Central Florida

Shelly Schoonover, MS, RN

Connors State College

Teresa Seefeldt, PharmD PhD

South Dakota State University

Sheela Vemu

Northern Illinois University

Technical Edits/Accuracy Panel

Patricia Dominguez, RN, MSN

Houston Baptist University

Ruby D. Johnson, MSN

Ozarka College

Bridgit R. Moore, EdD, MT (ASCP)

McLennan Community College

Maurice D. Taylor, CPhT, M.Th

Ultimate Medical Academy

Jana Tucker, CMA (AAMA), LRT

Salt Lake Community College



What Every Student Needs to Know

Many tools to help you learn have been integrated into *Pharmacology: An Introduction*.

Chapter Features

Learning Outcomes

present the key points you should focus on when reading the chapter. Consider this your road map to the knowledge and skills you will acquire upon studying this content.

Learning Outcomes

After studying this chapter, you should be able to:

36.1 describe the regulation of adrenocorticoid secretion especially glucocorticoid (cortisol) secretion.

36.2 explain the primary function of the glucocorticoids.

36.3. describe the clinical uses of the glucocorticoids

36.4 explain the function of the mineralocorticoid aldosterone.

36.5 describe special cautions and drug interactions that occur with steroid use.



Patient Administration and Monitoring

This class of drugs has a tremendous potential for overuse and overexposure due to the availability of over-the-counter preparations. In addition, steroids may be prescribed by more than one treating physician. It is not unusual for older patients to visit orthopedists, allergists, diabetologists, ophthalmologists, and rheumatologists in addition to their family physician. Therefore, it becomes important to review steroid actions that could be misinterpreted as exacerbations of other underlying conditions.

Time of Dosing

Single steroid doses should be taken before 9 AM to allow distribution of drug to mimic diurnal levels without suppressing available adrenocortical activity. Large doses of steroids may cause GI upset. Patients may take the medication with meals or antacids to minimize the irritation.

Changes in Blood Sugar Levels

Diabetics taking steroids must be properly counseled that steroids increase blood glucose otherwise they may overmedicate as a response to this transient hyperglycemia. Diabetic patients should notify the prescribing (steroid) physician if changes in their monitored blood glucose levels occur.

seizures, or headache occur. This may indicate the need for dose alteration or discontinuation if hypersensitivity develops. Topical steroids will more likely produce skin or ocular itching and irritation rather than the spectrum of other effects. Elderly patients should be reminded to call if they develop signs of hypertension, hyperglycemia, and potassium loss. These include dizziness, muscle weakness, and headaches. Because of the reduced muscle mass, elderly patients are more sensitized to the effects of steroids and should be monitored in the office at least every 6 months.

For patients receiving high doses of steroids, there is a decreased resistance to fight local infection (immunosuppressive response). Patients should notify the prescribing (steroid) physician before immunizations with live vaccines are given.

Stopping Medication

Patients receiving high-dose or long-term therapy should not discontinue steroids without supervision of the prescribing physician to avoid precipitating symptoms of withdrawal.

Use in Pregnancy

Drugs in this class have been designated FDA Pregnancy Cat.

Patient Administration and Monitoring boxes

summarize important patient information and patient instructions about the drugs discussed in that chapter. It will expand your knowledge of medications and conditions.

Notes to the Health Care Professional

emphasizes important points and information for medical personnel involved in drug administration.

Note to the Health-Care Professional

To avoid adrenal insufficiency, patients receiving high-dose or long-term steroid therapy must not discontinue treatment abruptly. These patients should be gradually weaned from the drug under the supervision of a physician.

Table 36:6

Examples of Drug Interactions Associated with Glucocorticoids


Glucocorticoids interact with	Response
Amphotericin B, digitalis, diuretics	Potentiate hypokalemia (possible digitalis toxicity)
Antibiotics, macrolide	Increase methylprednisolone clearance from plasma
Aspirin	Increase GI side effects by an additive effect
Growth hormone	Decrease growth-promoting effect of growth hormone
Insulin, oral hypoglycemics	Increase requirement for insulin or oral hypoglycemics
Isoniazid	Increase requirements for isoniazid
Oral contraceptives, estrogens, ketoconazole	Increase response of glucocorticoid and mineralocorticoid because of decreased steroid metabolism

Drug Tables

organize and summarize the main pharmacologic features of the different drug classes. The tables list the generic drug name first followed by the trade name(s), which are italicized and put within parentheses.

Illustrations and Photos

provide a dynamic visual picture of the action of drugs and drug products to help you understand pharmacological processes that are discussed in the text. Illustrations provide just the right level of detail to help explain the processes described.



Chapter Review



Understanding Terminology

Answer the following questions.

1. Define the term steroid. (LO 36.1)
2. Differentiate between mineralocorticoids and glucocorticoids. (LO 36.1)
3. Explain replacement therapy. (LO 36.3)

Acquiring Knowledge

Answer the following questions.

1. What are the two main parts of the adrenal gland? (LO 36.1)
2. Which layer of the adrenal cortex secretes the mineralocorticoids? Which layer secretes the glucocorticoids? (LO 36.1)
3. What disease results from a deficiency of the corticosteroids? (LO 36.3)
4. What three hormones regulate the release of cortisol? (LO 36.1)
5. What is the importance of higher glucocorticoid secretion during injury and wound healing? (LO 36.2)
6. List the two main therapeutic uses of the glucocorticoids. (LO 36.3)
7. What are the main differences between the naturally occurring steroids and the synthetic steroids? (LO 36.3)
8. List the major adverse effect of steroid therapy. What is meant by AD7? (LO 36.3)
9. What is the function of the mineralocorticoids? (LO 36.4)
10. What are the adverse effects of excessive administration of the mineralocorticoids? (LO 36.4)

Chapter Reviews

provide immediate reinforcement of terminology and pharmacological concepts important for acquiring knowledge. These questions, which are also available in Connect, challenge you to apply information presented in the chapter. The clinically relevant on-the-job questions allow you more opportunity to practice critical-thinking skills.

Appendix B


ABBREVIATIONS AND SYMBOLS COMMONLY USED IN MEDICAL NOTATIONS

Abbreviations			
Abbreviation	Meaning	Abbreviation	Meaning
a	before	CPE	complete physical examination
aa, AA	of each	CPR	cardiopulmonary resuscitation
a.c.	before meals	CSF	cerebrospinal fluid
ADD	attention deficit disorder	CT	computed tomography
ADL	activities of daily living	CV	cardiovascular
ad lib	as desired	d	day
ADT	admission, discharge, transfer	D&C	dilation and curettage
AIDS	acquired immunodeficiency syndrome	DEA	Drug Enforcement Administration
a.a.m.	against medical advice	DM, dM	diarrhea
AMA	American Medical Association	DM	diabetes mellitus
amp	ampule	DOB	date of birth
amt	amount	DTaP	diphtheria-tetanus-pertussis vaccine
aq, AQ	water; aqueous	Dr.	doctor
ansc.	anecdotation	DTs	delirium tremens
ax	axis	DW	dextrose in water
Bib, bib	drink	Dx, dx	diagnosis
b.i.d., bid, BID	twice a day	ECG, EKG	electrocardiogram
BM	board member	ED	emergency department

Appendices

provide additional information pertinent to the study of pharmacology. You will find lists of abbreviations and symbols used in medical notations, weights and measures, and mathematical functions and terms.





General Concepts

▶ CHAPTER 1

Pharmacology: An Introduction 4

▶ CHAPTER 2

Pharmacokinetics and Factors of Individual Variation 17


▶ CHAPTER 3

Geriatric Pharmacology 34

▶ CHAPTER 4

Math Review and Dosage Calculations 43





Pharmacology: An Introduction

KEY TERMS

adverse effect: general term for undesirable and potentially harmful drug effect.

agonist: drug that binds to a receptor and activates a physiologic response or drug action.

antagonist: drug that binds to a receptor and interferes with other drugs or substances from producing a drug effect.

chemical name: name that defines the chemical composition of a drug.

contraindications: situations or conditions when a certain drug should not be administered.

controlled substance: drug that has the potential for abuse and thus is regulated by law.

dose: a measurement of the amount of drug that is administered.

drug: chemical substance that produces a change in body function.

drug indications: intended or indicated uses for any drug.

ED50: effective dose 50, or dose that will produce an effect that is half of the maximal response.

generic name: nonproprietary name of a drug.

LD50: lethal dose 50, or dose that will kill 50 percent of the laboratory animals tested.

mechanism of action: explanation of how a drug produces its effects.

nonprescription, over-the-counter (OTC) drug: drug that can be purchased without the services of a physician.

pharmacology: study of drugs.

potency: measure of the strength, or concentration, of a drug required to produce a specific effect.

prescription drug: drug for which dispensing requires a written or phone order that can only be issued by or under the direction of a licensed physician.

receptor: specific cellular structure that a drug binds to in order to produce a physiologic effect.

side effect: drug effect other than the therapeutic effect that is usually undesirable but not harmful.

site of action: location within the body where a drug exerts its therapeutic effect, often a specific drug receptor.

therapeutic effect: desired drug effect to alleviate some condition or symptom of disease.

therapeutic index (TI): ratio of the LD50 to the ED50 in animal studies.

toxic effect: undesirable drug effect that implies drug poisoning; can be very harmful or life-threatening.

trade name: patented proprietary name of a drug sold by a specific drug manufacturer; also referred to as the brand name.

After studying this chapter, you should be able to:

- 1.1** list and define the major areas of pharmacology.
- 1.2** describe what a drug is and explain the differences between therapeutic effect, side effect, and toxic effect.
- 1.3** understand the terms **site of action** and **mechanism of action**, and how agonist and antagonist drugs interact at drug receptor sites.
- 1.4** characterize the relationship between drug dosage and drug response, and the relationship between drug response and time.
- 1.5** understand the terms associated with drug safety: therapeutic index, idiosyncrasy, drug allergy, and teratogen.
- 1.6** explain the nomenclature used to name and classify drugs.
- 1.7** recall the main drug references and the information they provide.

Pharmacology is the study of drugs. A drug can be any substance that, when administered to living organisms, produces a change in function. Thus, substances such as water, metals (iron), or insecticides can be classified as drugs. However, the term *drug* commonly refers to any medication that is used for diagnosing, curing, or treating disease.

Pharmacology is a subject that requires some background knowledge of anatomy, physiology, pathology, and related medical sciences. In that sense pharmacology is an integrative course of study that applies the relevant information of all medical sciences to the treatment of disease. Throughout this textbook the essential background information of anatomy, physiology, and pathology required for an understanding of drug action will be reviewed. The major focus of *Pharmacology: An Introduction* is to provide an understanding of the mechanisms of action, main therapeutic effects, clinical uses, and adverse reactions of drugs. Completion of an introductory pharmacology course is only the beginning step in understanding this complex subject.

LO 1.1

DRUG SOURCES AND MAJOR AREAS OF PHARMACOLOGY

Drug Sources

A logical question to ask about pharmacology is “Where do drugs come from?” There are several sources of drugs. In the early days of medicine, most drugs were obtained from plant or animal sources. Plants and living organisms contain active substances that can be isolated, purified, and formulated into effective drug preparations. Examples of drugs derived from plants that are still widely used today include the analgesics morphine and codeine, which were obtained from the poppy plant (*Papaver somniferum*); the heart drug digitalis, which was obtained from the purple foxglove (*Digitalis purpurea*); and the antimalarial drug quinine, which was obtained from the bark of the cinchona

tree. Paclitaxel, an anticancer drug, is obtained from the yew tree. The search for new plant drugs is still very active. It is also interesting that many of the drugs of abuse such as cocaine, marijuana, mescaline, heroin, and others are derived from plants. Most of these drugs were used for hundreds of years by many different cultures in their religious and ritual ceremonies. Drugs obtained from living organisms include hormones such as insulin (from the pig) and growth hormone from pituitary glands. In addition, antibiotics such as cephalosporins and aminoglycosides have been derived from bacteria. The early history of pharmacology is filled with many interesting stories of discovery and medical experimentation. Textbooks devoted to the history of medicine and pharmacology are the best sources for additional information. Despite the many examples of drugs obtained from plants and living organisms, the

Table 1:1

Major Areas of Pharmacology



Area	Description
Pharmacodynamics	Study of the action of drugs on living tissue
Pharmacokinetics	Study of the processes of drug absorption, distribution, metabolism, and excretion
Pharmacotherapeutics	Study of the use of drugs in treating disease
Pharmacy	Science of preparing and dispensing medicines
Posology	Study of the amount of drug that is required to produce therapeutic effects
Toxicology	Study of the harmful effects of drugs on living tissue

main source of new drugs today is from chemical synthesis. Also, many of the drugs that once were obtained from plants and animals are now chemically synthesized in pharmaceutical laboratories. Advances in molecular biology and gene therapy have generated new types of drugs such as monoclonal antibodies.

Pharmacology is a large discipline that can be subdivided into different areas of study. These include pharmacodynamics, pharmacokinetics, pharmacotherapeutics, pharmacy, posology, and toxicology. These areas of study are described in Table 1.1.

LO 1.2

TERMINOLOGY RELATED TO DRUG EFFECTS

Major Areas of Pharmacology

Another basic question that should be answered is “What actually is a **drug**?” Every pure drug is a chemical compound with a specific chemical structure. Because of its structure, a drug has certain properties that are usually divided into chemical properties and biological properties. The properties of any drug determine what effects will be produced when the drug is administered. An important fact to remember is that, structurally, the human body is composed mostly of cells, even though these cells are highly organized into tissues, organs, and systems. Consequently, drugs produce effects by influencing the function of cells.

Pharmacologists know that all drugs produce more than one effect. Every drug produces its intended

effect, or **therapeutic effect**, along with other effects. The therapeutic use(s) of any drug is referred to as the **drug indication**, meaning indications for use. The term **contraindication** refers to the situation or circumstance when a particular drug should *not* be used. Some drug effects, other than therapeutic effects, are described as undesirable. Undesired drug effects are categorized as side effects, adverse effects, and toxic effects.

Side Effects

Many **side effects** are more of a nuisance than they are harmful. The dry mouth and sedation caused by some antihistamine drugs is an example. In many cases drug side effects must be tolerated in order to benefit from the therapeutic actions of the drug.

Adverse Effects

Adverse effects are also undesired effects, but these are effects that may be harmful (persistent diarrhea, vomiting, or central nervous system [CNS] disturbances such as confusion) or that with prolonged treatment may cause conditions that affect the function of vital organs such as the liver or kidney. Reduction of dosage or switching to an alternative drug often will avoid or minimize these harmful consequences.

Toxic Effects

Toxic effects, or toxicity, implies drug poisoning, the consequences of which can be extremely harmful and may be life-threatening. In these situations, the drug must be stopped and supportive treatment and the administration of antidotes may be required.

The term most frequently used to describe the undesirable effects of drugs is *adverse effects*. However, you should be familiar with the other terms because they are used and, if used correctly, describe the nature and potential severity of undesired drug effects.

Most drugs will cause all three types of undesired effects, depending on the dose administered. At low doses, side effects are common and often expected. At higher doses, additional adverse effects may appear. At very high doses, toxic effects may occur that can be fatal. Consequently, the undesired effects produced by most drugs are often a function of dosage, which is why a well-known physician from the Middle Ages, Paracelsus (1493–1541), made the famous statement, “only the dose separates a drug from a poison”—and we could add, “a therapeutic effect from a toxic effect.” Allied health personnel spend the majority of their time in patient contact. Therefore, they have an important responsibility to observe the undesired effects of drugs, to recognize the side effects that are often expected, and to identify and report the adverse and toxic effects that are potentially harmful and that often require medical attention.

LO 1.3

BASIC CONCEPTS IN PHARMACOLOGY

As in any subject, fundamental principles and concepts form the basis upon which additional information can be added. Pharmacology is no exception, and the following basic concepts apply to any drug.

Site of Action

The **site of action** of a drug is the location within the body where the drug exerts its therapeutic effect. The site of action of some drugs is not known; however, the site of action for most drugs has been determined. For example, the site of action of aspirin to reduce fever is in an area of the brain known as the hypothalamus. Within the hypothalamus the temperature-regulating center controls and maintains body temperature. Aspirin alters the activity of the hypothalamus so that body temperature is reduced. Throughout this book, when the site of drug action is known or suspected, it will be presented.

Mechanism of Action

Mechanism of action explains how a drug produces its effects. For example, local anesthetic agents produce a loss of pain sensation by interrupting nerve conduction in sensory nerves. In order for nerve impulses to be conducted, sodium ions must pass through the nerve

membrane. Local anesthetic agents attach to the nerve membrane and prevent the passage of sodium ions. Consequently, sensory nerve impulses for pain are not conducted to the pain centers in the brain. Knowledge of the mechanism of action of drugs is essential to understanding why drugs produce the effects that they do.

Receptor Site

Drug action is usually thought to begin after a drug has attached itself to some chemical structure located on the outer cell membrane or within the cell itself. For a few drugs and for some normal body substances, there seems to be a specific location on certain cells. This area is referred to as the **receptor** site. The attachment, or binding, of a drug to its receptors begins a series of cell changes referred to as the drug action.

When a specific receptor site for a drug is known, that receptor site becomes the site of action for that particular drug. Morphine, an analgesic drug, is an example of a drug that binds to a specific receptor. The receptors for morphine are located in the brain and are known as the morphine, or opioid, receptors. When morphine binds to its receptors, it produces cell changes that reduce the perception of pain. There are many different pharmacological receptors, and they will be described in the appropriate chapters.

Agonists and Antagonists


Drugs that bind to specific receptors and produce a drug action are called **agonists**. Morphine is an example of an agonist. Drugs that bind to specific receptors and block agonist drug action or cellular functions are called **antagonists**.

Antagonists are also known as blocking drugs. Usually, antagonists bind to a specific receptor to displace or prevent an agonist drug or body substance from activating that receptor. Naloxone, a morphine antagonist, is administered to prevent, or antagonize, the effects of morphine in cases of morphine overdose. There are many examples in pharmacology where drug antagonists are used to prevent other substances from exerting an effect.

When both agonist and antagonist drugs bind to the same receptor and are administered together, they compete with each other for the same receptor site. This effect is known as *competitive antagonism*. The amount of drug action produced depends on which drug (agonist or antagonist) occupies the greatest number of receptors. The actions of a drug agonist and antagonist are illustrated in Figure 1.1. There is also uncompetitive antagonism, which occurs when the antagonist drug interferes with the agonist drug action but not by binding to the same receptor.

Figure 1.1

Competitive Antagonism at Work



LO 1.4

DOSE-RESPONSE AND TIME-PLASMA DRUG CONCENTRATION CURVES

Dose-Response Curve

A fundamental principle of pharmacology is that the response to any drug depends on the amount of drug given. This principle is known as the dose-response relationship. A **dose** is the exact amount of a drug that is administered in order to produce a specific effect. The effect is referred to as the response. When the relationship between the dose and the response is plotted as a graph, it is referred to as a dose-response curve.

Figure 1.2 illustrates the appearance of a typical dose-response curve for two similar drugs. The main feature of the dose-response relationship is that a drug response is proportional to the dose. As the dose increases, so does the magnitude of the response. Eventually, a *maximal response* is usually attained (100 percent response); further increases in dose do not produce any greater effect. This point on the graph is known as the ceiling effect. The *ceiling effect* reflects the limit of some drug classes to produce a particular effect. Above a certain dosage no further increase in effect is observed. Doses above those needed to produce the ceiling effect usually cause other undesired, often toxic, drug effects. Drugs within a drug class that are more potent than other drugs in the same class will produce the ceiling effect at a lower dosage, but they will not “raise the ceiling.”

Drugs that continue to cause an increased effect as long as the dose is increased do not have a ceiling effect.

A graded dose-response curve can be used to evaluate drug response among different drugs. In a graded dose-response curve, the increases in drug dosage are plotted against the increases in drug response. For example, dose-response curves are used to compare the potency of similar drugs. **Potency** is a measure of the strength, or concentration, of a drug required to produce a specific effect. The dose that will produce an effect that is half of the maximal response is referred to as the effective dose 50, or **ED50**.

The ED50 can be used to compare the potency of drugs that produce the same response. In Figure 1.2, the ED50 of drug A is 10 mg while the ED50 of drug B is 20 mg. Therefore, drug A is twice as potent as drug B. Twice the concentration of drug B is needed to produce the same response as drug A.

Quantal (referred to as all-or-none) dose-response curves are used to show the percentage of a human or animal population that responds to a specific drug dosage. This information is important for determining the dosages that are recommended for various treatments. Quantal dose-response curves require an understanding of mathematical statistics that is beyond the scope of this textbook.

Time-Plasma Drug Concentration Curve

The relationship of time and the plasma drug concentration is known as the time-plasma drug concentration curve or time-response curve since it reflects the duration of action. *Duration of action* is the length of time that a drug continues to produce its effect. Most

Figure 1.2

A Typical Dose-Response Curve





Figure 1.3

A Typical Time-Plasma Drug Concentration Curve



This curve shows the change in plasma drug concentration over time in relation to onset, duration, and termination of drug action. Plasma drug concentrations that exceed the therapeutic range produce drug toxicity.

individual drugs produce effects over a relatively constant period of time. Figure 1.3 illustrates the appearance of a typical time-plasma drug concentration curve. In this example, the plasma drug concentration is correlated with the onset, duration, and termination of drug action. After drug administration, a certain amount of time is required before a drug will produce an observable effect. The time from drug administration to the first observable effect is known as the *onset of action*. The drug response will continue as long as there is an effective concentration of the drug at the site of action. As the drug is metabolized and excreted, the response gradually decreases because the drug level is decreasing. When the plasma drug concentration falls below the therapeutic range, there is *termination of drug action*. Time-plasma drug concentration curves are used for predicting the frequency with which a drug must be administered in order to maintain an effective drug response.

LO 1.5

DRUG SAFETY

The federal Food and Drug Administration (FDA) has established guidelines that govern the approval and use of all drugs. Every drug must fulfill two major requirements before it can be approved for use in humans: efficacy (proof of effectiveness) and safety. The drug must be effective in the disease state for which it has been approved. Approved drugs must satisfy specific safety criteria as determined by extensive animal testing and controlled human testing. As discussed previously, the dose separates therapeutic effects from toxic effects.

Note to the Health Care Professional

All drugs will act as poisons if taken in excess. Only the dose separates a therapeutic effect from a toxic effect. The goal of drug therapy is to select a dose that is in the therapeutic range and avoid doses that produce toxicity. This task is not easy because many factors influence the amount of drug that reaches its site of action. These factors—such as route of administration, absorption, and drug metabolism—will be discussed in Chapter 2, Pharmacokinetics and Factors of Individual Variation.

Drug safety receives much attention today. It is a constant source of concern and debate because the public is more aware of the dangers of drugs. In order to receive approval for use in humans, a drug must undergo several years of both animal and human testing and evaluation. Several animal species must be used in order to evaluate the effectiveness and toxicity of a drug. One of the first tests that is performed is the lethal dose 50, or **LD50**. The LD50 is the dose that will kill 50 percent of the animals tested. The results of the LD50 and other tests are used to predict the safety of a drug.

Therapeutic Index

The **therapeutic index (TI)** is a ratio of the LD50 to the ED50 of a drug. It gives an estimate of the relative safety of a drug. The equation is expressed as:

$$TI = LD50/ED50 = 1000 \text{ mg}/100 \text{ mg} = 10$$

In this example, the therapeutic index is 10. This index indicates that ten times as much drug is needed to produce a lethal effect in 50 percent of the animals as is needed to produce the therapeutic effect in 50 percent of the animals. The therapeutic index is used only in animal studies to establish dosage levels for other testing procedures. The goal of drug therapy is to achieve therapeutic effects in all individuals without producing any harmful effects.

Adverse Drug Effects

All drugs produce adverse and toxic effects if taken in excess. Most adverse effects are dose dependent, which means the higher the dose, the greater the chances for producing an adverse effect. Certain tissues are more